{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Unfractionated+heparin&page=2",
    "query": {
      "intervention": "Unfractionated heparin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 444,
    "total_pages": 45,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Unfractionated+heparin&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Unfractionated+heparin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T23:22:24.495Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00321009",
      "title": "LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Acute Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corewell Health East",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2000-03",
      "completion_date": "2004-04",
      "has_results": false,
      "last_update_posted_date": "2006-05-03",
      "last_synced_at": "2026-09-30T23:22:24.495Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Royal Oak, Michigan • Syracuse, New York + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Greensboro",
          "state": "North Carolina"
        },
        {
          "city": "Doylestown",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00321009"
    },
    {
      "nct_id": "NCT02206087",
      "title": "Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PER977",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Heparin Sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2014-06",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2020-05-21",
      "last_synced_at": "2026-09-30T23:22:24.495Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02206087"
    },
    {
      "nct_id": "NCT05414305",
      "title": "The Female Microbiome in Patients Undergoing Bladder Instillation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Cystitis",
        "Bladder Pain Syndrome",
        "Microbial Colonization"
      ],
      "interventions": [
        {
          "name": "Heparin & Alkalinized Lidocaine Bladder Instillation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walter Reed National Military Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2020-10-01",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-08-14",
      "last_synced_at": "2026-09-30T23:22:24.495Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05414305"
    },
    {
      "nct_id": "NCT01014403",
      "title": "Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2009-11",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2021-01-13",
      "last_synced_at": "2026-09-30T23:22:24.495Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Tyler, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01014403"
    },
    {
      "nct_id": "NCT03594045",
      "title": "Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heparin-induced Thrombocytopenia",
        "Heparin-induced Thrombocytopenia and Thrombosis"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-12-18",
      "completion_date": "2019-10-30",
      "has_results": true,
      "last_update_posted_date": "2020-12-23",
      "last_synced_at": "2026-09-30T23:22:24.495Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03594045"
    },
    {
      "nct_id": "NCT02739100",
      "title": "Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Triferic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rockwell Medical Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2016-04",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2019-02-01",
      "last_synced_at": "2026-09-30T23:22:24.495Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02739100"
    },
    {
      "nct_id": "NCT01029821",
      "title": "Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Deep Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Low-Molecular-Weight Heparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Tennessee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 100,
      "start_date": "2010-02",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2011-06-16",
      "last_synced_at": "2026-09-30T23:22:24.495Z",
      "location_count": 1,
      "location_summary": "Chattanooga, Tennessee",
      "locations": [
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01029821"
    },
    {
      "nct_id": "NCT05426031",
      "title": "Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coagulation; Intravascular"
      ],
      "interventions": [
        {
          "name": "Protamine fixed dose",
          "type": "DRUG"
        },
        {
          "name": "Protamine ratio dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2022-06-28",
      "completion_date": "2023-06-01",
      "has_results": true,
      "last_update_posted_date": "2024-08-13",
      "last_synced_at": "2026-09-30T23:22:24.495Z",
      "location_count": 2,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05426031"
    },
    {
      "nct_id": "NCT00854139",
      "title": "Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide, anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Kidney transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Thymic irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Bone marrow transplant from a related donor",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2001-08",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2020-03-04",
      "last_synced_at": "2026-09-30T23:22:24.495Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00854139"
    },
    {
      "nct_id": "NCT05879835",
      "title": "KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pediatric Intestinal Failure"
      ],
      "interventions": [
        {
          "name": "KiteLock 4% Sterile Catheter Lock Solution",
          "type": "DEVICE"
        },
        {
          "name": "Heparin Lock Solution",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "SterileCare Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "4 Weeks to 18 Years"
      },
      "enrollment_count": 124,
      "start_date": "2024-06-21",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-30T23:22:24.495Z",
      "location_count": 8,
      "location_summary": "Boston, Massachusetts • Omaha, Nebraska • New York, New York + 5 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05879835"
    }
  ]
}